3.20
+0.47(+17.22%)
Currency In USD
| Previous Close | 2.73 |
| Open | 2.82 |
| Day High | 3.2 |
| Day Low | 2.82 |
| 52-Week High | 4.75 |
| 52-Week Low | 1.92 |
| Volume | 100,557 |
| Average Volume | 76,061 |
| Market Cap | 91.52M |
| PE | -0.84 |
| EPS | -3.79 |
| Moving Average 50 Days | 3.03 |
| Moving Average 200 Days | 2.8 |
| Change | 0.47 |
If you invested $1000 in OncoCyte Corporation (OCX) since IPO date, it would be worth $19.8 as of July 16, 2025 at a share price of $3.2. Whereas If you bought $1000 worth of OncoCyte Corporation (OCX) shares 5 years ago, it would be worth $112.68 as of July 16, 2025 at a share price of $3.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology
GlobeNewswire Inc.
May 19, 2025 8:05 PM GMT
New price of $2,753 for the GraftAssureCore™ assay increases total addressable market size and margin opportunityBrings pricing in line with existing competitive technologyExpands market appeal for prospective FDA-cleared kitted product at transplant
Oncocyte to Release First Quarter 2025 Results on May 12, 2025
GlobeNewswire Inc.
May 07, 2025 8:10 PM GMT
IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Onco
Oncocyte Provides Positive Update on Clinical Trial Progress
GlobeNewswire Inc.
Apr 30, 2025 12:30 PM GMT
Central Institutional Review Board approved, final preparatory steps underway at first transplant centersThree of the top 10 U.S. transplant centers expected to participate in trialNearly 10% of annual U.S. transplant volume represented in trial site
Data not available